Inclusion Criteria:

          -  Male or female, aged between 18 and 75 years of age undergoing allogeneic
             hematopoietic stem cell transplantation (alloHCT) or the treatment of Acute Myeloid
             Leukemia (AML) with detectable minimal residual disease (MRD) either before or after
             alloHCT

          -  Have < 5% blasts in bone marrow by morphology at the time of transplantation but
             pre-alloHCT flow cytometric or molecular evidence of MRD

          -  Karnofsky performance status (KPS) ≥ 70% during the study screening.

          -  Free of symptomatic congestive heart failure or uncontrolled arrhythmia

          -  Adequate organ function as defined per protocol

          -  Negative serum pregnancy test

          -  Note: Women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control or abstinence) prior to
             study entry and for at least 30 days following study treatment (T-cell infusion);
             should a woman subject or female partner of a male subject become pregnant or suspect
             that she is pregnant while participating on the trial, she should inform her treating
             physician immediately.

          -  Provision of signed and dated informed consent form

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study.

          -  Agreement to adhere to Lifestyle Considerations throughout study duration

        Exclusion Criteria:

          -  Current use of concomitant systemic glucocorticoid for any reason will not be allowed
             in order to avoid their immunosuppressive effects on γδ T-cell function.

          -  Active grade II-IV acute GVHD (patients with prior GVHD should be off prednisone for
             at least 14 days prior to infusion of the study cell product).

          -  Uncontrolled serious infection.

          -  Morphologic relapse of leukemia at any timepoint after HCT.

          -  Active central nervous system malignancy.

          -  Pregnancy or lactation.

          -  Treatment with another investigational drug or other intervention within 14 days of
             T-cell infusion